Cardiac Glycosides Induce Cell Death in Human Cells by Inhibiting General Protein Synthesis
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Cardiac glycosides are Na(+)/K(+)-pump inhibitors widely used to treat heart failure. They are also highly cytotoxic, and studies have suggested specific anti-tumor activity leading to current clinical trials in cancer patients. However, a definitive demonstration of this putative anti-cancer activity and the underlying molecular mechanism has remained elusive. METHODOLOGY/PRINCIPAL FINDINGS: Using an unbiased transcriptomics approach, we found that cardiac glycosides inhibit general protein synthesis. Protein synthesis inhibition and cytotoxicity were not specific for cancer cells as they were observed in both primary and cancer cell lines. These effects were dependent on the Na(+)/K(+)-pump as they were rescued by expression of a cardiac glycoside-resistant Na(+)/K(+)-pump. Unlike human cells, rodent cells are largely resistant to cardiac glycosides in vitro and mice were found to tolerate extremely high levels. CONCLUSIONS/SIGNIFICANCE: The physiological difference between human and mouse explains the previously observed sensitivity of human cancer cells in mouse xenograft experiments. Thus, published mouse xenograft models used to support anti-tumor activity for these drugs require reevaluation. Our finding that cardiac glycosides inhibit protein synthesis provides a mechanism for the cytotoxicity of CGs and raises concerns about ongoing clinical trials to test CGs as anti-cancer agents in humans.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lamb, J., Crawford, E. D., Peck, D., Modell, J. W., Blat, I. C., Wrobel, M. J., Lerner, J., Brunet, J.-P., Subramanian, A., Ross, K. N., et al. (2006) · Science · doi:10.1126/science.1132939 · Cited by 5,257
Motzer, R. J., Escudier, B., Oudard, S., Hutson, T. E., Porta, C., Bracarda, S., Grünwald, V., Thompson, J. A., Figlin, R. A., Hollaender, N., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61039-9 · Cited by 3,019 · cited 2×
“As general protein synthesis inhibitors have not proven useful as cancer therapeutics, it is highly unlikely that the effects of CGs on protein synthesis can be successfully exploited to treat cancer [25,26,27,28,29,30].”
BackgroundNovel therapeutic applications of cardiac glycosides
Prassas, I., & Diamandis, E. P. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2682 · Cited by 673
Digoxin and other cardiac glycosides inhibit HIF-1α synthesis and block tumor growth
Zhang, H., Qian, D. Z., Tan, Y. S., Lee, K., Gao, P., Ren, Y. R., Rey, S., Hammers, H., Chang, D., Pili, R., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809763105 · Cited by 624 · cited 4×
“CGs show in vitro activity against a broad range of cell types and a number of compound screens have recently rediscovered that CGs inhibit proliferation in various assays [2,5,6,7].”
BackgroundMethodInfluentialIs digitalis a therapy for breast carcinoma?
Stenkvist, B. (1999) · Oncology Reports · doi:10.3892/or.6.3.493 · Cited by 160
Different protein turnover of interleukin‐6‐type cytokine signalling components
Siewert, E., Müller‐Esterl, W., Starr, R., Heinrich, P. C., & Schaper, F. (1999) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.1999.00719.x · Cited by 121
Simpson, C. D., Mawji, I. A., Anyiwe, K., Williams, M. A., Wang, X., Venugopal, A. L., Gronda, M., Hurren, R., Cheng, S., Serra, S., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2530 · Cited by 104
INADA, A., NAKANISHI, T., KONOSHIMA, T., KOZUKA, M., TOKUDA, H., NISHINO, H., & IWASHIMA, A. (1993) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.16.930 · Cited by 34
Cited by
Consensus guidelines for the detection of immunogenic cell death
Kepp, O., Senovilla, L., Vitale, I., Vacchelli, E., Adjemian, S., Agostinis, P., Apetoh, L., Aranda, F., Barnaba, V., Bloy, N., et al. (2014) · OncoImmunology · doi:10.4161/21624011.2014.955691 · Cited by 832
Cardiac Glycosides Exert Anticancer Effects by Inducing Immunogenic Cell Death
Menger, L., Vacchelli, E., Adjemian, S., Martins, I., Ma, Y., Shen, S., Yamazaki, T., Sukkurwala, A. Q., Michaud, M., Mignot, G., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003807 · Cited by 423
Sleire, L., Førde, H. E., Netland, I. A., Leiss, L., Skeie, B. S., & Enger, P. Ø. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.07.013 · Cited by 329
“treatment as digitoxin inhibits general protein synthesis in both malignant and nonmalignant cells (80).”
Anticancer steroids: linking natural and semi-synthetic compounds
Salvador, J. A. R., Carvalho, J. F. S., Neves, M. A. C., Silvestre, S. M., Leitão, A. J., Silva, M. M. C., & Sá e Melo, M. L. (2013) · Nat. Prod. Rep. · doi:10.1039/c2np20082a · Cited by 276
Modulation of endothelial organelle size as an antithrombotic strategy
Ferraro, F., Patella, F., Costa, J. R., Ketteler, R., Kriston‐Vizi, J., & Cutler, D. F. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15084 · Cited by 19
Metadata
- Authors
- Perne, A., Muellner, M. K., Steinrueck, M., Craig-Mueller, N., Mayerhofer, J., Schwarzinger, I., Sloane, M., Uras, I. Z., Hoermann, G., Nijman, S. M. B., & Mayerhofer, M.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2009-12-16
- Volume
- 4
- Issue
- 12
- Pages
- e8292
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2006665219
- Cited by
- 83
- References
- 8
- FWCI
- 2.04
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cardiac Glycosides Induce Cell Death in Human Cells by Inhibiting General Protein Synthesis. https://app.cochat.ai/papers/10.1371/journal.pone.0008292
- The paper
- Perne, A., Muellner, M. K., Steinrueck, M., Craig-Mueller, N., Mayerhofer, J., Schwarzinger, I., Sloane, M., Uras, I. Z., Hoermann, G., Nijman, S. M. B., & Mayerhofer, M. (2009). Cardiac Glycosides Induce Cell Death in Human Cells by Inhibiting General Protein Synthesis. PLoS ONE. https://doi.org/10.1371/journal.pone.0008292
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.